Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 108

1.

Synthetic Lethal Interaction of SHOC2 Depletion with MEK Inhibition in RAS-Driven Cancers.

Sulahian R, Kwon JJ, Walsh KH, Pailler E, Bosse TL, Thaker M, Almanza D, Dempster JM, Pan J, Piccioni F, Dumont N, Gonzalez A, Rennhack J, Nabet B, Bachman JA, Goodale A, Lee Y, Bagul M, Liao R, Navarro A, Yuan TL, Ng RWS, Raghavan S, Gray NS, Tsherniak A, Vazquez F, Root DE, Firestone AJ, Settleman J, Hahn WC, Aguirre AJ.

Cell Rep. 2019 Oct 1;29(1):118-134.e8. doi: 10.1016/j.celrep.2019.08.090.

2.

Germline BRCA-associated Endometrial Carcinoma is a Distinct Clinicopathologic Entity.

de Jonge MM, Ritterhouse LL, de Kroon CD, Vreeswijk MPG, Segal JP, Puranik R, Study H, Hollema H, Rookus MA, van Asperen CJ, Van Leeuwen FE, Smit VTHBM, Howitt BE, Bosse T.

Clin Cancer Res. 2019 Sep 6. pii: clincanres.0848.2019. doi: 10.1158/1078-0432.CCR-19-0848. [Epub ahead of print]

PMID:
31492746
3.

High numbers of activated helper T cells are associated with better clinical outcome in early stage vulvar cancer, irrespective of HPV or p53 status.

Kortekaas KE, Santegoets SJ, Abdulrahman Z, van Ham VJ, van der Tol M, Ehsan I, van Doorn HC, Bosse T, van Poelgeest MIE, van der Burg SH.

J Immunother Cancer. 2019 Sep 3;7(1):236. doi: 10.1186/s40425-019-0712-z.

4.

Practical Guidance for Measuring and Reporting Surgical Margins in Vulvar Cancer.

Kortekaas KE, Van de Vijver KK, van Poelgeest MIE, Gilks CB, Smit VTHBM, Arif S, Arora D, Faruqi A, Ganesan R, Griffin NR, Hale R, Hock YE, Horn LC, McCluggage WG, Mukonoweshuro P, Park KJ, Rous B, Tanchel B, Van Rompuy AS, van Schalkwyk G, Vella J, Vergine M, Singh N, Bosse T.

Int J Gynecol Pathol. 2019 Aug 26. doi: 10.1097/PGP.0000000000000631. [Epub ahead of print]

PMID:
31460873
5.

Selecting Adjuvant Treatment for Endometrial Carcinoma Using Molecular Risk Factors.

Wortman BG, Nout RA, Bosse T, Creutzberg CL.

Curr Oncol Rep. 2019 Jul 31;21(9):83. doi: 10.1007/s11912-019-0825-z. Review.

6.

Lynch syndrome screening in gynaecological cancers: results of an international survey with recommendations for uniform reporting terminology for mismatch repair immunohistochemistry results.

Ryan N, Wall J, Crosbie EJ, Arends M, Bosse T, Arif S, Faruqi A, Frayling I, Ganesan R, Hock YL, McMahon R, Manchanda R, McCluggage WG, Mukonoweshuro P, van Schalkwyk G, Side L, Smith JH, Tanchel B, Evans DG, Gilks CB, Singh N.

Histopathology. 2019 Jul 16. doi: 10.1111/his.13925. [Epub ahead of print]

PMID:
31310679
7.

Validating Automated Sentiment Analysis of Online Cognitive Behavioral Therapy Patient Texts: An Exploratory Study.

Provoost S, Ruwaard J, van Breda W, Riper H, Bosse T.

Front Psychol. 2019 May 14;10:1065. doi: 10.3389/fpsyg.2019.01065. eCollection 2019.

8.

Reproducibility of lymphovascular space invasion (LVSI) assessment in endometrial cancer.

Peters EEM, Bartosch C, McCluggage WG, Genestie C, Lax SF, Nout R, Oosting J, Singh N, Smit HCSH, Smit VTHBM, Van de Vijver KK, Bosse T.

Histopathology. 2019 Jul;75(1):128-136. doi: 10.1111/his.13871. Epub 2019 Jun 10.

PMID:
31155736
9.

Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data.

Cohen PA, Powell A, Böhm S, Gilks CB, Stewart CJR, Meniawy TM, Bulsara M, Avril S, Brockbank EC, Bosse T, de Azevedo Focchi GR, Ganesan R, Glasspool RM, Howitt BE, Kim HS, Lee JY, Le ND, Lockley M, Manchanda R, Mandalia T, McCluggage WG, McNeish I, Midha D, Srinivasan R, Tan YY, van der Griend R, Yunokawa M, Zannoni GF; HGSC CRS Collaborative Network (Supplementary 1), Singh N.

Gynecol Oncol. 2019 Aug;154(2):441-448. doi: 10.1016/j.ygyno.2019.04.679. Epub 2019 May 19. Review.

10.

ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach.

Luchini C, Bibeau F, Ligtenberg MJL, Singh N, Nottegar A, Bosse T, Miller R, Riaz N, Douillard JY, Andre F, Scarpa A.

Ann Oncol. 2019 May 6. pii: mdz116. doi: 10.1093/annonc/mdz116. [Epub ahead of print]

PMID:
31056702
11.

An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity.

Kopper O, de Witte CJ, Lõhmussaar K, Valle-Inclan JE, Hami N, Kester L, Balgobind AV, Korving J, Proost N, Begthel H, van Wijk LM, Revilla SA, Theeuwsen R, van de Ven M, van Roosmalen MJ, Ponsioen B, Ho VWH, Neel BG, Bosse T, Gaarenstroom KN, Vrieling H, Vreeswijk MPG, van Diest PJ, Witteveen PO, Jonges T, Bos JL, van Oudenaarden A, Zweemer RP, Snippert HJG, Kloosterman WP, Clevers H.

Nat Med. 2019 May;25(5):838-849. doi: 10.1038/s41591-019-0422-6. Epub 2019 Apr 22.

PMID:
31011202
12.

The Manchester International Consensus Group recommendations for the management of gynecological cancers in Lynch syndrome.

Crosbie EJ, Ryan NAJ, Arends MJ, Bosse T, Burn J, Cornes JM, Crawford R, Eccles D, Frayling IM, Ghaem-Maghami S, Hampel H, Kauff ND, Kitchener HC, Kitson SJ, Manchanda R, McMahon RFT, Monahan KJ, Menon U, Møller P, Möslein G, Rosenthal A, Sasieni P, Seif MW, Singh N, Skarrott P, Snowsill TM, Steele R, Tischkowitz M; Manchester International Consensus Group, Evans DG.

Genet Med. 2019 Oct;21(10):2390-2400. doi: 10.1038/s41436-019-0489-y. Epub 2019 Mar 28.

13.

A Transcriptionally Distinct CXCL13+CD103+CD8+ T-cell Population Is Associated with B-cell Recruitment and Neoantigen Load in Human Cancer.

Workel HH, Lubbers JM, Arnold R, Prins TM, van der Vlies P, de Lange K, Bosse T, van Gool IC, Eggink FA, Wouters MCA, Komdeur FL, van der Slikke EC, Creutzberg CL, Kol A, Plat A, Glaire M, Church DN, Nijman HW, de Bruyn M.

Cancer Immunol Res. 2019 May;7(5):784-796. doi: 10.1158/2326-6066.CIR-18-0517. Epub 2019 Mar 14.

PMID:
30872264
14.

MGL Ligand Expression Is Correlated to Lower Survival and Distant Metastasis in Cervical Squamous Cell and Adenosquamous Carcinoma.

Sahasrabudhe NM, van der Horst JC, Spaans V, Kenter G, de Kroon C, Bosse T, van Vliet SJ, Jordanova ES.

Front Oncol. 2019 Jan 29;9:29. doi: 10.3389/fonc.2019.00029. eCollection 2019.

15.

Integrated Molecular Analysis of Undifferentiated Uterine Sarcomas Reveals Clinically Relevant Molecular Subtypes.

Binzer-Panchal A, Hardell E, Viklund B, Ghaderi M, Bosse T, Nucci MR, Lee CH, Hollfelder N, Corcoran P, Gonzalez-Molina J, Moyano-Galceran L, Bell DA, Schoolmeester JK, Måsbäck A, Kristensen GB, Davidson B, Lehti K, Isaksson A, Carlson JW.

Clin Cancer Res. 2019 Apr 1;25(7):2155-2165. doi: 10.1158/1078-0432.CCR-18-2792. Epub 2019 Jan 7.

PMID:
30617134
16.

Frequent Homologous Recombination Deficiency in High-grade Endometrial Carcinomas.

de Jonge MM, Auguste A, van Wijk LM, Schouten PC, Meijers M, Ter Haar NT, Smit VTHBM, Nout RA, Glaire MA, Church DN, Vrieling H, Job B, Boursin Y, de Kroon CD, Rouleau E, Leary A, Vreeswijk MPG, Bosse T.

Clin Cancer Res. 2019 Feb 1;25(3):1087-1097. doi: 10.1158/1078-0432.CCR-18-1443. Epub 2018 Nov 9.

PMID:
30413523
17.

Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy.

Wortman BG, Creutzberg CL, Putter H, Jürgenliemk-Schulz IM, Jobsen JJ, Lutgens LCHW, van der Steen-Banasik EM, Mens JWM, Slot A, Kroese MCS, van Triest B, Nijman HW, Stelloo E, Bosse T, de Boer SM, van Putten WLJ, Smit VTHBM, Nout RA; PORTEC Study Group.

Br J Cancer. 2018 Oct;119(9):1067-1074. doi: 10.1038/s41416-018-0310-8. Epub 2018 Oct 25.

PMID:
30356126
18.

Adjuvant therapy for high-risk endometrial cancer: recent evidence and future directions.

De Boer SM, Nout RA, Bosse T, Creutzberg CL.

Expert Rev Anticancer Ther. 2019 Jan;19(1):51-60. doi: 10.1080/14737140.2019.1531708. Epub 2018 Oct 24. Review.

PMID:
30295094
19.

The immune cell infiltrate in the microenvironment of vulvar Paget disease.

van der Linden M, van Esch E, Bulten J, Dreef E, Massuger L, van der Steen S, Bosse T, de Hullu J, van Poelgeest M.

Gynecol Oncol. 2018 Dec;151(3):453-459. doi: 10.1016/j.ygyno.2018.09.026. Epub 2018 Sep 28.

PMID:
30274932
20.

Independent validation of the prognostic significance of invasion patterns in endocervical adenocarcinoma: Pattern A predicts excellent survival.

Spaans VM, Scheunhage DA, Barzaghi B, de Kroon CD, Fleuren GJ, Bosse T, Jordanova ES.

Gynecol Oncol. 2018 Nov;151(2):196-201. doi: 10.1016/j.ygyno.2018.09.013. Epub 2018 Sep 24.

PMID:
30262404
21.

Metabolic Analysis of Drosophila melanogaster Larval and Adult Brains.

Neville KE, Bosse TL, Klekos M, Mills JF, Tipping M.

J Vis Exp. 2018 Aug 7;(138). doi: 10.3791/58007.

22.

L1CAM expression in uterine carcinosarcoma is limited to the epithelial component and may be involved in epithelial-mesenchymal transition.

Versluis M, Plat A, de Bruyn M, Matias-Guiu X, Trovic J, Krakstad C, Nijman HW, Bosse T, de Bock GH, Hollema H.

Virchows Arch. 2018 Nov;473(5):591-598. doi: 10.1007/s00428-018-2444-8. Epub 2018 Aug 23.

PMID:
30140948
23.

Molecular-integrated risk profile to determine adjuvant radiotherapy in endometrial cancer: Evaluation of the pilot phase of the PORTEC-4a trial.

Wortman BG, Bosse T, Nout RA, Lutgens LCHW, van der Steen-Banasik EM, Westerveld H, van den Berg H, Slot A, De Winter KAJ, Verhoeven-Adema KW, Smit VTHBM, Creutzberg CL; PORTEC Study Group.

Gynecol Oncol. 2018 Oct;151(1):69-75. doi: 10.1016/j.ygyno.2018.07.020. Epub 2018 Aug 3.

24.

Movember GAP1 PDX project: An international collection of serially transplantable prostate cancer patient-derived xenograft (PDX) models.

Navone NM, van Weerden WM, Vessella RL, Williams ED, Wang Y, Isaacs JT, Nguyen HM, Culig Z, van der Pluijm G, Rentsch CA, Marques RB, de Ridder CMA, Bubendorf L, Thalmann GN, Brennen WN, Santer FR, Moser PL, Shepherd P, Efstathiou E, Xue H, Lin D, Buijs J, Bosse T, Collins A, Maitland N, Buzza M, Kouspou M, Achtman A, Taylor RA, Risbridger G, Corey E.

Prostate. 2018 Dec;78(16):1262-1282. doi: 10.1002/pros.23701. Epub 2018 Aug 2.

PMID:
30073676
25.

Refinement of high-risk endometrial cancer classification using DNA damage response biomarkers: a TransPORTEC initiative.

Auguste A, Genestie C, De Bruyn M, Adam J, Le Formal A, Drusch F, Pautier P, Crosbie EJ, MacKay H, Kitchener HC, Powell M, Pollock PM, Mileshkin L, Edmondson RJ, Nout R, Nijman HW, Creutzberg CL, Bosse T, Leary A.

Mod Pathol. 2018 Dec;31(12):1851-1861. doi: 10.1038/s41379-018-0055-1. Epub 2018 Jun 28.

PMID:
29955143
26.

Validation and Implementation of BRCA1/2 Variant Screening in Ovarian Tumor Tissue.

de Jonge MM, Ruano D, van Eijk R, van der Stoep N, Nielsen M, Wijnen JT, Ter Haar NT, Baalbergen A, Bos MEMM, Kagie MJ, Vreeswijk MPG, Gaarenstroom KN, Kroep JR, Smit VTHBM, Bosse T, van Wezel T, van Asperen CJ.

J Mol Diagn. 2018 Sep;20(5):600-611. doi: 10.1016/j.jmoldx.2018.05.005. Epub 2018 Jun 21.

27.

Molecular risk stratification to direct therapy in endometrial cancer: ready for the clinic?

Creutzberg CL, Bosse T.

Ann Oncol. 2018 May 1;29(5):1081-1082. doi: 10.1093/annonc/mdy098. No abstract available.

PMID:
29668827
28.

Somatic POLE exonuclease domain mutations are early events in sporadic endometrial and colorectal carcinogenesis, determining driver mutational landscape, clonal neoantigen burden and immune response.

Temko D, Van Gool IC, Rayner E, Glaire M, Makino S, Brown M, Chegwidden L, Palles C, Depreeuw J, Beggs A, Stathopoulou C, Mason J, Baker AM, Williams M, Cerundolo V, Rei M, Taylor JC, Schuh A, Ahmed A, Amant F, Lambrechts D, Smit VT, Bosse T, Graham TA, Church DN, Tomlinson I.

J Pathol. 2018 Jul;245(3):283-296. doi: 10.1002/path.5081. Epub 2018 Apr 30.

29.

Adjuvant Treatment for POLE Proofreading Domain-Mutant Cancers: Sensitivity to Radiotherapy, Chemotherapy, and Nucleoside Analogues.

Van Gool IC, Rayner E, Osse EM, Nout RA, Creutzberg CL, Tomlinson IPM, Church DN, Smit VTHBM, de Wind N, Bosse T, Drost M.

Clin Cancer Res. 2018 Jul 1;24(13):3197-3203. doi: 10.1158/1078-0432.CCR-18-0266. Epub 2018 Mar 20.

30.

Authors' Reply.

McAlpine JN, Bosse T.

J Pathol. 2018 Jun;245(2):251. doi: 10.1002/path.5067. Epub 2018 Apr 17. No abstract available.

PMID:
29512825
31.

Molecular Classification of Grade 3 Endometrioid Endometrial Cancers Identifies Distinct Prognostic Subgroups.

Bosse T, Nout RA, McAlpine JN, McConechy MK, Britton H, Hussein YR, Gonzalez C, Ganesan R, Steele JC, Harrison BT, Oliva E, Vidal A, Matias-Guiu X, Abu-Rustum NR, Levine DA, Gilks CB, Soslow RA.

Am J Surg Pathol. 2018 May;42(5):561-568. doi: 10.1097/PAS.0000000000001020.

32.

Folate receptor-α targeted near-infrared fluorescence imaging in high-risk endometrial cancer patients: a tissue microarray and clinical feasibility study.

Boogerd LSF, Hoogstins CES, Gaarenstroom KN, de Kroon CD, Beltman JJ, Bosse T, Stelloo E, Vuyk J, Low PS, Burggraaf J, Vahrmeijer AL.

Oncotarget. 2017 Dec 11;9(1):791-801. doi: 10.18632/oncotarget.23155. eCollection 2018 Jan 2.

33.

A remarkable response to pazopanib, despite recurrent liver toxicity, in a patient with a high grade endometrial stromal sarcoma, a case report.

Verschoor AJ, Warmerdam FARM, Bosse T, Bovée JVMG, Gelderblom H.

BMC Cancer. 2018 Jan 22;18(1):92. doi: 10.1186/s12885-018-3999-0.

34.

The rise of a novel classification system for endometrial carcinoma; integration of molecular subclasses.

McAlpine J, Leon-Castillo A, Bosse T.

J Pathol. 2018 Apr;244(5):538-549. doi: 10.1002/path.5034. Epub 2018 Feb 28. Review.

PMID:
29344951
35.

Gynaecological neoplasms in common familial syndromes (Lynch and HBOC).

Bartosch C, Clarke B, Bosse T.

Pathology. 2018 Feb;50(2):222-237. doi: 10.1016/j.pathol.2017.10.010. Epub 2017 Dec 26. Review.

PMID:
29287922
36.

A novel ex vivo method for measuring whole brain metabolism in model systems.

Neville KE, Bosse TL, Klekos M, Mills JF, Weicksel SE, Waters JS, Tipping M.

J Neurosci Methods. 2018 Feb 15;296:32-43. doi: 10.1016/j.jneumeth.2017.12.020. Epub 2017 Dec 26.

37.

Clinical consequences of upfront pathology review in the randomised PORTEC-3 trial for high-risk endometrial cancer.

de Boer SM, Wortman BG, Bosse T, Powell ME, Singh N, Hollema H, Wilson G, Chowdhury MN, Mileshkin L, Pyman J, Katsaros D, Carinelli S, Fyles A, McLachlin CM, Haie-Meder C, Duvillard P, Nout RA, Verhoeven-Adema KW, Putter H, Creutzberg CL, Smit VTHBM; for PORTEC Study Group.

Ann Oncol. 2018 Feb 1;29(2):424-430. doi: 10.1093/annonc/mdx753.

38.

L1 cell adhesion molecule (L1CAM) is a strong predictor for locoregional recurrences in cervical cancer.

Schrevel M, Corver WE, Vegter ME, Ter Haar NT, Dreef EJ, Beltman JJ, Kenter G, Bosse T, de Kroon CD, Jordanova ES.

Oncotarget. 2017 Sep 18;8(50):87568-87581. doi: 10.18632/oncotarget.20976. eCollection 2017 Oct 20.

39.

Amplification of 1q32.1 Refines the Molecular Classification of Endometrial Carcinoma.

Depreeuw J, Stelloo E, Osse EM, Creutzberg CL, Nout RA, Moisse M, Garcia-Dios DA, Dewaele M, Willekens K, Marine JC, Matias-Guiu X, Amant F, Lambrechts D, Bosse T.

Clin Cancer Res. 2017 Dec 1;23(23):7232-7241. doi: 10.1158/1078-0432.CCR-17-0566. Epub 2017 Sep 22.

40.

Genomic Characterization of Vulvar (Pre)cancers Identifies Distinct Molecular Subtypes with Prognostic Significance.

Nooij LS, Ter Haar NT, Ruano D, Rakislova N, van Wezel T, Smit VTHBM, Trimbos BJBMZ, Ordi J, van Poelgeest MIE, Bosse T.

Clin Cancer Res. 2017 Nov 15;23(22):6781-6789. doi: 10.1158/1078-0432.CCR-17-1302. Epub 2017 Sep 12.

41.

A novel keratin 13 variant in a four-generation family with white sponge nevus.

de Haseth SB, Bakker E, Vermeer MH, El Idrissi H, Bosse T, Smit VTHBM, Terron-Kwiatkowski A, McLean WHI, Peters AAW, Hes FJ.

Clin Case Rep. 2017 Jul 29;5(9):1503-1509. doi: 10.1002/ccr3.1073. eCollection 2017 Sep.

42.

The Paget Trial: A Multicenter, Observational Cohort Intervention Study for the Clinical Efficacy, Safety, and Immunological Response of Topical 5% Imiquimod Cream for Vulvar Paget Disease.

van der Linden M, Meeuwis K, van Hees C, van Dorst E, Bulten J, Bosse T, IntHout J, Boll D, Slangen B, van Seters M, van Beurden M, van Poelgeest M, de Hullu J.

JMIR Res Protoc. 2017 Sep 6;6(9):e178. doi: 10.2196/resprot.7503.

43.

Blinded histopathological characterisation of POLE exonuclease domain-mutant endometrial cancers: sheep in wolf's clothing.

Van Gool IC, Ubachs JEH, Stelloo E, de Kroon CD, Goeman JJ, Smit VTHBM, Creutzberg CL, Bosse T.

Histopathology. 2018 Jan;72(2):248-258. doi: 10.1111/his.13338. Epub 2017 Oct 10.

PMID:
28795426
44.

Markers of the p53 pathway further refine molecular profiling in high-risk endometrial cancer: A TransPORTEC initiative.

Edmondson RJ, Crosbie EJ, Nickkho-Amiry M, Kaufmann A, Stelloo E, Nijman HW, Leary A, Auguste A, Mileshkin L, Pollock P, MacKay HJ, Powell ME, Bosse T, Creutzberg CL, Kitchener HC.

Gynecol Oncol. 2017 Aug;146(2):327-333. doi: 10.1016/j.ygyno.2017.05.014. Epub 2017 May 13.

PMID:
28511869
45.

Limited impact of intratumour heterogeneity on molecular risk assignment in endometrial cancer.

van Esterik M, Van Gool IC, de Kroon CD, Nout RA, Creutzberg CL, Smit VTHBM, Bosse T, Stelloo E.

Oncotarget. 2017 Apr 11;8(15):25542-25551. doi: 10.18632/oncotarget.16067.

46.

Immunological profiling of molecularly classified high-risk endometrial cancers identifies POLE-mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition.

Eggink FA, Van Gool IC, Leary A, Pollock PM, Crosbie EJ, Mileshkin L, Jordanova ES, Adam J, Freeman-Mills L, Church DN, Creutzberg CL, De Bruyn M, Nijman HW, Bosse T.

Oncoimmunology. 2016 Dec 9;6(2):e1264565. doi: 10.1080/2162402X.2016.1264565. eCollection 2017.

47.

Potential Targets' Analysis Reveals Dual PI3K/mTOR Pathway Inhibition as a Promising Therapeutic Strategy for Uterine Leiomyosarcomas-an ENITEC Group Initiative.

Cuppens T, Annibali D, Coosemans A, Trovik J, Ter Haar N, Colas E, Garcia-Jimenez A, Van de Vijver K, Kruitwagen RP, Brinkhuis M, Zikan M, Dundr P, Huvila J, Carpén O, Haybaeck J, Moinfar F, Salvesen HB, Stukan M, Mestdagh C, Zweemer RP, Massuger LF, Mallmann MR, Wardelmann E, Mints M, Verbist G, Thomas D, Gommé E, Hermans E, Moerman P, Bosse T, Amant F.

Clin Cancer Res. 2017 Mar 1;23(5):1274-1285. doi: 10.1158/1078-0432.CCR-16-2149.

48.

Linking uterine serous carcinoma to BRCA1/2-associated cancer syndrome: A meta-analysis and case report.

de Jonge MM, Mooyaart AL, Vreeswijk MP, de Kroon CD, van Wezel T, van Asperen CJ, Smit VT, Dekkers OM, Bosse T.

Eur J Cancer. 2017 Feb;72:215-225. doi: 10.1016/j.ejca.2016.11.028. Epub 2016 Dec 31. Review.

PMID:
28049106
49.

Ki-67 in endometrial cancer: scoring optimization and prognostic relevance for window studies.

Kitson S, Sivalingam VN, Bolton J, McVey R, Nickkho-Amiry M, Powell ME, Leary A, Nijman HW, Nout RA, Bosse T, Renehan AG, Kitchener HC, Edmondson RJ, Crosbie EJ.

Mod Pathol. 2017 Mar;30(3):459-468. doi: 10.1038/modpathol.2016.203. Epub 2016 Dec 2.

50.

Loss of ARID1A Activates ANXA1, which Serves as a Predictive Biomarker for Trastuzumab Resistance.

Berns K, Sonnenblick A, Gennissen A, Brohée S, Hijmans EM, Evers B, Fumagalli D, Desmedt C, Loibl S, Denkert C, Neven P, Guo W, Zhang F, Knijnenburg TA, Bosse T, van der Heijden MS, Hindriksen S, Nijkamp W, Wessels LF, Joensuu H, Mills GB, Beijersbergen RL, Sotiriou C, Bernards R.

Clin Cancer Res. 2016 Nov 1;22(21):5238-5248. Epub 2016 May 12.

Supplemental Content

Support Center